NASDAQ:BCEL

Atreca (BCEL) Stock Forecast, Price & News

$0.23

+0.00 (+0.04%)

(As of 12:44 PM ET)

Compare

Today's Range: $0.23
▼
$0.25
50-Day Range: $0.23
▼
$0.98
52-Week Range: $0.23
▼
$2.05

Volume: 43,682 shs
Average Volume: 161,170 shs
Market Capitalization: $9.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.75

Atreca MarketRank™ Forecast

Analyst Rating: Hold
2.20 Rating Score
Upside/Downside: 4,416.8% Upside
$10.75 Price Target
Short Interest: Bearish
9.38% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$9,085 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.64) to ($0.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

3.1

Analyst's Opinion

Consensus Rating
Atreca has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.75, Atreca has a forecasted upside of 4,416.8% from its current price of $0.24.
Amount of Analyst Coverage
Atreca has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.38% of the float of Atreca has been sold short.
Short Interest Ratio / Days to Cover
Atreca has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Atreca has recently decreased by 2.51%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Atreca does not currently pay a dividend.
Dividend Growth
Atreca does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Atreca has received a 72.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Atreca is -0.85.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Atreca this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atreca insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,085.00 in company stock.
Percentage Held by Insiders
11.30% of the stock of Atreca is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 34.91% of the stock of Atreca is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Atreca are expected to grow in the coming year, from ($1.64) to ($0.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atreca is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atreca is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atreca has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Atreca (NASDAQ:BCEL) Stock

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

BCEL Price History

30 days | 90 days | 365 days | Advanced Chart

BCEL Stock News Headlines

September 30, 2023 | americanbankingnews.com

Atreca, Inc. (NASDAQ:BCEL) Receives Average Recommendation of "Hold" from Analysts

September 21, 2023 | finance.yahoo.com

Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross

October 4, 2023 | Behind the Markets (Ad)

BREAKING: The truth about war with China

Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.

August 11, 2023 | msn.com

HC Wainwright & Co. Downgrades Atreca Inc - (BCEL)

August 11, 2023 | msn.com

Stifel Downgrades Atreca Inc - (BCEL)

August 11, 2023 | finance.yahoo.com

Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring

August 2, 2023 | msn.com

Atreca Inc - (BCEL) Price Target Increased by 11.89% to 10.20

June 20, 2023 | msn.com

Atreca Approaches A Major Go/No-Go Decision

October 4, 2023 | Behind the Markets (Ad)

BREAKING: The truth about war with China

June 6, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Atreca (BCEL)

June 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Atreca Inc - (BCEL) Buy Recommendation

June 5, 2023 | finance.yahoo.com

Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting

June 5, 2023 | markets.businessinsider.com

Atreca (BCEL) Gets a Buy from H.C. Wainwright

June 2, 2023 | fool.com

Atreca (NASDAQ: BCEL)

May 30, 2023 | markets.businessinsider.com

Stifel Nicolaus Sticks to Their Buy Rating for Atreca (BCEL)

May 17, 2023 | ca.finance.yahoo.com

Atreca, Inc. (BCEL) Interactive Stock Chart - Yahoo Finance

May 14, 2023 | ca.finance.yahoo.com

Atreca, Inc. (BCEL) Stock Historical Prices & Data - Yahoo Finance

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Atreca, Inc. (BCEL) Buy Recommendation

May 11, 2023 | msn.com

Stifel Maintains Atreca, Inc. (BCEL) Buy Recommendation

May 11, 2023 | finanznachrichten.de

Atreca, Inc.: Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 11, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Atreca (BCEL) and Oscar Health (OSCR)

May 10, 2023 | finance.yahoo.com

Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments

April 26, 2023 | finance.yahoo.com

Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting

April 13, 2023 | finance.yahoo.com

Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

April 6, 2023 | finance.yahoo.com

Here's Why Atreca, Inc. (BCEL) Is a Great 'Buy the Bottom' Stock Now

April 5, 2023 | finance.yahoo.com

Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

March 23, 2023 | finance.yahoo.com

Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

See More Headlines

Receive BCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter.

BCEL Company Calendar

Last Earnings: 8/10/2023
Today: 10/04/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BCEL
CUSIP: N/A
CIK: 1532346
Web: www.atreca.com
Phone: (650) 595-2595
Fax: N/A
Employees: 90
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.75
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +4,416.8%
Consensus Rating: Hold
Rating Score (0-4): 2.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-97,160,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -120.73%
Return on Assets: -58.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.49
Quick Ratio: 3.49

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.01 per share
Price / Book: 0.12

Miscellaneous

Outstanding Shares: 39,300,000
Free Float: 34,856,000
Market Cap: $9.35 million
Optionable: Not Optionable
Beta: 1.24

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. John A. Orwin M.B.A. (Age 58)
Pres, CEO, Director & Principal Financial Officer
Comp: $927.03k

Dr. Tito A. Serafini Ph.D. (Age 60)
Founder, Chief Strategy Officer & Director
Comp: $665.5k

Dr. Stephen E. Gould Ph.D. (Age 58)
Chief Scientific Officer
Comp: $380.52k

Mr. Rick Ruiz (Age 59)
Principal Accounting Officer

Ms. Courtney J. Phillips J.D. (Age 48)
Gen. Counsel & Corp. Sec.

Dr. Philippe C. Bishop M.D. (Age 58)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCEL Stock - Frequently Asked Questions

Should I buy or sell Atreca stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares.
View BCEL analyst ratings or view top-rated stocks.
What is Atreca's stock price forecast for 2023?: 5 brokers have issued 1-year target prices for Atreca's stock. Their BCEL share price forecasts range from $4.00 to $25.00. On average, they predict the company's share price to reach $10.75 in the next year. This suggests a possible upside of 4,416.8% from the stock's current price.
View analysts price targets for BCEL or view top-rated stocks among Wall Street analysts.
How have BCEL shares performed in 2023?: Atreca's stock was trading at $0.8006 at the beginning of the year. Since then, BCEL shares have decreased by 70.3% and is now trading at $0.2380.
View the best growth stocks for 2023 here.
When is Atreca's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BCEL earnings forecast.
How were Atreca's earnings last quarter?: Atreca, Inc. (NASDAQ:BCEL) posted its earnings results on Thursday, August, 10th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.07.
What is John Orwin's approval rating as Atreca's CEO?: 6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend.

What other stocks do shareholders of Atreca own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Akero Therapeutics (AKRO), Hookipa Pharma (HOOK), Lumentum (LITE), TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL).
When did Atreca IPO?: (BCEL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.
What is Atreca's stock symbol?: Atreca trades on the NASDAQ under the ticker symbol "BCEL."
How do I buy shares of Atreca?: Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Atreca's stock price today?: One share of BCEL stock can currently be purchased for approximately $0.24.
How much money does Atreca make?: Atreca (NASDAQ:BCEL) has a market capitalization of $9.35 million. The company earns $-97,160,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.
How can I contact Atreca?: Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The official website for the company is www.atreca.com. The company can be reached via phone at (650) 595-2595 or via email at ir@atreca.com.

This page (NASDAQ:BCEL) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial